

## AMENDMENTS TO THE CLAIMS:

The following is a complete list of the pending claims.

1. (Currently amended) A pharmaceutical composition comprising one or more isolated peptides selected from the group consisting of:
  - a) a peptide having the sequence of SEQ ID NO:30 ~~any of SEQ ID NO:1 to SEQ ID NO:36~~;
  - b) a peptide homologous to SEQ ID NO:30 ~~any one of SEQ ID NO:1 to SEQ ID NO:36~~ from another flavivirus; and
  - c) a peptide functionally equivalent to SEQ ID NO:30 ~~any one of SEQ ID NO:1 to SEQ ID NO:36~~, wherein the functionally equivalent peptide is identical to SEQ ID NO:30 ~~at least one of SEQ ID NO:1 to SEQ ID NO:36~~ except that one or more amino acid residues has been substituted with a homologous amino acid, resulting in a functionally silent change, or one or more amino acids has been deleted.
  
2. (Currently amended) A pharmaceutical composition comprising ~~at least one~~ or more isolated peptides ~~peptide~~ selected from the ~~one or more of the~~ following:
  - a) a peptide having the amino acid sequence ~~one or more of~~ SEQ ID NO:30 ~~SEQ ID NO:1 to SEQ ID NO:36~~, wherein the N-terminal amino acid residue comprises an N-terminal amino group and the C-terminal amino acid residue comprises a ~~e-terminal~~ C-terminal carboxyl group;
  - b) a peptide having the sequence of SEQ ID NO:30 ~~any of SEQ ID NO:1 to SEQ ID NO:36~~, wherein the chemical moiety at the peptide's N-terminus is not an amino group or wherein ~~and/or~~ the chemical moiety at the peptide's C-terminus is not a carboxyl group, wherein the N-terminal chemical moiety is selected from the group consisting of: an acetyl group, a hydrophobic group, carbobenzoxy group, dansyl group, a t-butyloxycarbonyl group, and ~~and~~ ~~or~~ ~~or~~ a macromolecular carrier group, or ~~and/or~~ wherein the C-terminal chemical moiety is selected from the group consisting of an amido group, a hydrophobic group, t-butyloxycarbonyl group and ~~and~~ ~~or~~ ~~or~~ a macromolecular group;

- c) a peptide having the sequence of SEQ ID NO:30 ~~any of SEQ ID NO:1 to SEQ ID NO:36~~, wherein at least one bond linking adjacent amino acid residues is a non-peptide bond;
- d) a peptide having the sequence of SEQ ID NO:30 ~~any of SEQ ID NO:1 to SEQ ID NO:36~~, wherein at least one amino acid residue is in the D-isomer configuration;
- e) a peptide as in part "a)" or "b)" except that at least one amino acid has been substituted ~~[[for]]~~ by a different amino acid; or
- f) a functional fragment of a peptide as set out in any of parts "a)" to "e)", having at least 3 contiguous amino acids ~~nucleotides~~ of SEQ ID NO:30 ~~any one of SEQ ID NO:1 to SEQ ID NO:36~~.

3-14. (Cancelled)

- 15. (Currently amended) The composition of claim 2 wherein the selected peptide comprises SEQ ID NO:30 ~~is selected from one or more of the group consisting of SEQ ID NO:6-9, 14-17, 22-25, and 30-33.~~
- 16. (Currently amended) The composition of claim 15 wherein the N-terminal chemical moiety is an acetyl group, a hydrophobic group, a carbobenzoxy group, a dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group; or wherein ~~and/or~~ the C-terminal chemical moiety is a hydrophobic group, a t-butyloxycarbonyl group or a macromolecular group.
- 17. (Currently amended) The composition of claim 15 wherein the N-terminal chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate; or ~~and/or~~ the C-terminal chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate.
- 18. (Previously presented) The composition of claim 15 wherein at least one bond linking adjacent amino acid residues in the peptide is a non-peptide bond selected from the group consisting of an imido bond, an ester bond, a hydrazine bond, a semicarbazoid bond and an azo bond.

19. (Original) The composition of claim 15 wherein at least one amino acid is a D-isomer amino acid.
20. (Previously presented) The composition of claim 15 wherein the N-terminal chemical moiety is an amino group and the C-terminal chemical moiety is a carboxyl group.
- 21-26. (Cancelled)
27. (Withdrawn) A method of treating or preventing a Flavivirus infection comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 1.
28. (Withdrawn) A method of treating or preventing a Flavivirus infection comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 2.
- 29-30. (Cancelled)
31. (New) The composition of claim 2 wherein the selected peptide consists of SEQ ID NO:30.